![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division ... Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States. Show more
U.S. index futures are registering a significant drop in pre-market trading this Wednesday, with the technology sector being the most affected. At 5:50 AM, Dow Jones futures (DOWI:DJI) fell 78...
Spirit Airlines (NYSE:SAVE) – Spirit Airlines reduced its revenue forecast for the second quarter to $1.28 billion, down from the previous estimate of $1.32-1.34 billion, due to lower...
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company’s common stock. The...
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19...
NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is leveraging a multi-pathway approach to transform...
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung...
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study PR Newswire RARITAN, N.J., July 2...
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients PR Newswire HELSINKI, June 28, 2024...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 4.4 | 2.92767316521 | 150.29 | 157.49 | 148.87 | 8640315 | 154.03993438 | CS |
4 | 5.69 | 3.81879194631 | 149 | 157.49 | 144.5 | 6618636 | 149.60516096 | CS |
12 | 8.55 | 5.85055426304 | 146.14 | 157.49 | 143.71 | 7242038 | 148.74614053 | CS |
26 | -7.31 | -4.51234567901 | 162 | 163.58 | 143.13 | 7407557 | 152.55997933 | CS |
52 | -16.81 | -9.80174927114 | 171.5 | 175.97 | 143.13 | 11107119 | 160.73093681 | CS |
156 | -14.71 | -8.68358913813 | 169.4 | 186.69 | 143.13 | 8483077 | 164.79304496 | CS |
260 | 24.69 | 18.9923076923 | 130 | 186.69 | 109.16 | 8166557 | 157.95056196 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions